Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12507906 | 1.00 | CNR1 (0.61) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2187500 | 1.00 | CNR1 (0.61) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL12508159 | 0.96 | CNR1 (0.57) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2189515 | 0.96 | CNR1 (0.57) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2189516 | 0.96 | CNR1 (0.57) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2190517 | 0.95 | CNR1 (0.58) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14771281 | 0.95 | CNR1 (0.58) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2189818 | 0.95 | CNR1 (0.58) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14762843 | 0.95 | CNR1 (0.58) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL2189816 | 0.95 | CNR1 (0.58) | CNR1ALDH1A1FAAHCNR2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | claimed |
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | claimed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | claimed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | claimed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | claimed |
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | RAJASEKHAR VIJAYKUMAR (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9289503-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2949344-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | FH, FABP3, HMGCR | CNR1 4358/4885ALDH1A1 1637/4885FAAH 258/4885 |
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | FABP3, FH, TNNI3 | CNR1 3874/4885ALDH1A1 648/4885FAAH 750/4885 |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885FAAH 147/4885 |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885FAAH 147/4885 |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885FAAH 147/4885 |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | GAA, GUSB, ACER2 | CNR1 3616/4885ALDH1A1 1139/4885FAAH 766/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885FAAH 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.